-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atamparib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atamparib in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atamparib in Mantle Cell Lymphoma Drug Details: Atamparib (RBN-2397) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atamparib in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atamparib in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atamparib in Breast Cancer Drug Details: Atamparib (RBN-2397) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atamparib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atamparib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atamparib in Solid Tumor Drug Details: Atamparib (RBN-2397) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atamparib in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atamparib in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atamparib in Head And Neck Squamous Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISN-001 in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISN-001 in Epidermolysis Bullosa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISN-001 in Epidermolysis Bullosa Drug Details: ISN-001 (ALLO-ASC) is under development...
-
Product Insights
Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Systemic Sclerosis (Scleroderma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Drugs In Development, 2023’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Endometrial Cancer Drug Details: Zanidatamab is under development for the treatment of HER2-expressing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EVO-101 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EVO-101 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EVO-101 in Atopic Dermatitis (Atopic Eczema) Drug Details:EVO-101 is under development...